Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the former's pipeline amid significant vaccine policy changes in the US. The transaction, for a price of$15.50 per share in cash, is expected to close in the first quarter of 2026. Through the deal, Sanofi will acquire Dynavax's hepatitis B vaccine HEPLISAV-B. The product won approval in the US and Europe in 2017 and 2021, respectively. Sanofi does not currently have a hepatitis B vacc ...